AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26080652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 23021253 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly/passive priming
Number of subjects: 59
Study 23021253 — intervention group
Group type: EXPERIMENTAL
Intervention: Youthful/active priming
Number of subjects: 59
Study 20206352 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microg of misoprostol sublingually plus 800 microg of misoprostol vaginally or orally, readministered after 24 hours if no response or incomplete abortion.
Number of subjects: 454
Study 19034870 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin-alpha (EPO-alpha) to maintain hemoglobin levels in the range 12-14 g/dL, median final dose 2,000 IU/week.
Number of subjects: 95
Study 19034870 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment unless hemoglobin decreased to 9.0 g/dL).
Number of subjects: 95
Study 19034870 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin-alpha (EPO-alpha) treatment group.
Number of subjects: 95
Study 19034870 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment).
Number of subjects: 95
Study 17163135 — intervention group
Group type: EXPERIMENTAL
Intervention: Twinrix
Number of subjects: 200
Study 17163135 — intervention group
Group type: COMPARATOR
Intervention: Havrix and Engerix-B
Number of subjects: 200
Study 17163135 — intervention group
Group type: EXPERIMENTAL
Intervention: Twinrix and monovalent vaccines
Number of subjects: 200
Study 12019005 — intervention group
Group type: EXPERIMENTAL
Intervention: Palate re-repairs using the operating microscope with radical dissection and retropositioning of the velar muscles
Number of subjects: 85
Study 9829116 — intervention group
Group type: EXPERIMENTAL
Intervention: Nidek KM‐800
Number of subjects: 30
Study 9829116 — intervention group
Group type: EXPERIMENTAL
Intervention: Nikon NRK‐8000
Number of subjects: 30
Study 9829116 — intervention group
Group type: COMPARATOR
Intervention: Bausch and Lomb keratometer
Number of subjects: 30
Study 7628128 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescue angioplasty
Number of subjects: 0
Study 7628128 — intervention group
Group type: COMPARATOR
Intervention: Thrombolytic therapy
Number of subjects: 0
Study 2082318 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 10 mg
Number of subjects: 206
Study 2082318 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 20 mg
Number of subjects: 206
Study 2082318 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 206
Study 2082318 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 600 mg
Number of subjects: 206
Study 2082318 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen-codeine 600 mg plus 60 mg
Number of subjects: 206
Study 2082318 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study 117953 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (MCP) stimulation
Number of subjects: 35
Study 117953 — intervention group
Group type: COMPARATOR
Intervention: Insulin induced hypoglycaemia
Number of subjects: 35
Study 7058581 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative intercostal nerve block with bupivacaine hydrochloride
Number of subjects: 90
Study 7058581 — intervention group
Group type: COMPARATOR
Intervention: Placebo nerve block
Number of subjects: 90
Study 31492790 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation
Number of subjects: 0
Study 31492790 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 0
Study 30053472 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated SMS reminders containing information about diabetic retinopathy, sent 1 week and 3 days prior to scheduled eye appointments.
Number of subjects: 233
Study 30053472 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated SMS reminders
Number of subjects: 233
Study 30053472 — intervention group
Group type: COMPARATOR
Intervention: Control group (no reminders)
Number of subjects: 233
Study 27931291 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 5 µg once daily (n = 25)
Number of subjects: 53
Study 27931291 — intervention group
Group type: COMPARATOR
Intervention: No add-on (n = 28)
Number of subjects: 53
Study 25096030 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump CABG
Number of subjects: 308
Study 25096030 — intervention group
Group type: COMPARATOR
Intervention: On-pump CABG
Number of subjects: 308
Study 22257879 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental composites with filler contents of 80%, 76%, 70%, 60%, and 50% by weight
Number of subjects: 25
Study 22257879 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental composites with varying filler contents
Number of subjects: 25
Study 19918201 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-infrared tissue spectrometer InSpectra (Hutchinson Technology Inc.) measuring StO2 on bicep muscle
Number of subjects: 310
Study 19918201 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-infrared tissue spectrometer InSpectra (Hutchinson Technology Inc.) measuring StO2 on deltoid muscle
Number of subjects: 310
Study 19918201 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-infrared tissue spectrometer InSpectra (Hutchinson Technology Inc.) measuring StO2 on thenar eminence
Number of subjects: 310
Study 19918201 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-infrared tissue spectrometer InSpectra (Hutchinson Technology Inc.) measuring StO2 on other areas (forearm, calf, tricep)
Number of subjects: 310
Study 19918201 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-infrared tissue spectrometer InSpectra (Hutchinson Technology Inc.) measuring StO2
Number of subjects: 310
Study 17365773 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Internet sites (highly utilized)
Number of subjects: 6451
Study 17365773 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Internet sites (less utilized)
Number of subjects: 6451
Study 17365773 — intervention group
Group type: COMPARATOR
Intervention: Static Internet site with quitting advice
Number of subjects: 6451
Study 16332600 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (5FU/levamisole for 12 months, n = 444; 5FU/leucovorin for 4-5 months, n = 262; 5FU/leucovorin with +/- levamisole, n = 397)
Number of subjects: 2224
Study 16332600 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 2224
Study 12006716 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal buserelin acetate 300 microg 6 times daily for 2 years
Number of subjects: 46
Study 12006716 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous Suprefact Depot 6.3 mg every 8 weeks for the third year
Number of subjects: 46
Study 12006716 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone treatment in addition to pubertal inhibition (randomized in half of the girls)
Number of subjects: 46
Study 9864110 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery (laparoscopic procedure)
Number of subjects: 32
Study 9864110 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 32
Study 7615321 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovoid bars with a resilient joint
Number of subjects: 2
Study 7615321 — intervention group
Group type: COMPARATOR
Intervention: Parallel-sided bars with a rigid joint
Number of subjects: 2
Study 2117205 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine surfactant (SF‐RI 1)
Number of subjects: 0
Study 728283 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous metoclopramide (10 mg)
Number of subjects: 7
Study 31754964 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate group (n=17)
Number of subjects: 34
Study 31754964 — intervention group
Group type: COMPARATOR
Intervention: Waitlist group (n=17)
Number of subjects: 34
Study 30472901 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (EXPg) using brain-sensing devices
Number of subjects: 55
Study 30472901 — intervention group
Group type: COMPARATOR
Intervention: Active control group (CONTg)
Number of subjects: 55
Study 27589411 — intervention group
Group type: EXPERIMENTAL
Intervention: Permissive underfeeding with full protein intake
Number of subjects: 894
Study 27589411 — intervention group
Group type: COMPARATOR
Intervention: Standard feeding
Number of subjects: 894
Study 27589411 — intervention group
Group type: EXPERIMENTAL
Intervention: Permissive underfeeding
Number of subjects: 894
Study 24887970 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-based peer feedback through social networking
Number of subjects: 41
Study 24887970 — intervention group
Group type: COMPARATOR
Intervention: Control group (no peer feedback)
Number of subjects: 41
Study 25276712 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational and modifying intervention about asthma triggers
Number of subjects: 60
Study 25276712 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 60
Study 21383359 — intervention group
Group type: EXPERIMENTAL
Intervention: GRACE intervention (in-home assessments by a nurse practitioner and a social worker)
Number of subjects: 951
Study 21383359 — intervention group
Group type: EXPERIMENTAL
Intervention: GRACE intervention
Number of subjects: 951
Study 21383359 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 951
Study 19951217 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral metronidazole
Number of subjects: 126
Study 19951217 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal metronidazole
Number of subjects: 126
Study 19951217 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 126
Study 18018467 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planning plus systematic use of doxycycline
Number of subjects: 46
Study 15159227 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate n-6 PUFA diet + 4.0 g fish oil/d (2.5 g eicosapentaenoic acid + docosahexaenoic acid)
Number of subjects: 29
Study 15159227 — intervention group
Group type: EXPERIMENTAL
Intervention: High n-6 PUFA diet + 4.0 g fish oil/d (2.5 g eicosapentaenoic acid + docosahexaenoic acid)
Number of subjects: 29
Study 15159227 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.0 g fish oil/d (2.5 g eicosapentaenoic acid + docosahexaenoic acid) after 6 weeks of dietary intervention
Number of subjects: 29
Study 11953878 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg intravenous clodronate
Number of subjects: 86
Study 11953878 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg intravenous clodronate
Number of subjects: 86
Study 11953878 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg intravenous clodronate
Number of subjects: 86
Study 11953878 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 mg intravenous clodronate
Number of subjects: 86
Study 9797079 — intervention group
Group type: EXPERIMENTAL
Intervention: CD45-negative B-cell precursor ALL
Number of subjects: 638
Study 9797079 — intervention group
Group type: COMPARATOR
Intervention: CD45-positive B-cell precursor ALL
Number of subjects: 638
Study 9797079 — intervention group
Group type: EXPERIMENTAL
Intervention: CD45-negative subpopulation
Number of subjects: 638
Study 7639232 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg
Number of subjects: 268
Study 7639232 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg
Number of subjects: 268
Study 7639232 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 60 mg
Number of subjects: 268
Study 7639232 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 268
Study 2146057 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (5 mg every 12 hours)
Number of subjects: 18
Study 2146057 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (90 mg every 8 hours)
Number of subjects: 18
Study 2146057 — intervention group
Group type: COMPARATOR
Intervention: Placebo (every 12 hours)
Number of subjects: 18
Study 369651 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose (alpha-glucosidehydrolase inhibitor) taken with food
Number of subjects: 7
Study 369651 — intervention group
Group type: COMPARATOR
Intervention: Dummy tablets (control)
Number of subjects: 7
Study 30986302 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal administration of 16.1 mg of ASAL‐HM
Number of subjects: 26
Study 30986302 — intervention group
Group type: COMPARATOR
Intervention: Intranasal administration of 8.0 mg of HM (control)
Number of subjects: 26
Study 30986302 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal administration of ASAL‐HM
Number of subjects: 26
Study 31829233 — intervention group
Group type: EXPERIMENTAL
Intervention: Budget tool developed by KCE Trials programme
Number of subjects: 17
Study 31829233 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-reducing measures (multistep selection process, advance payments, recruitment feasibility check, close monitoring, milestone-based payment schedule)
Number of subjects: 17
Study 30055692 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival injection with 40 mg triamcinolone acetonide
Number of subjects: 213
Study 30055692 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injection with 1.25 mg bevacizumab
Number of subjects: 213
Study 30055692 — intervention group
Group type: COMPARATOR
Intervention: No additional treatment
Number of subjects: 213
Study 30055692 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of subconjunctival triamcinolone acetonide and intravitreal bevacizumab
Number of subjects: 213
Study 27817811 — intervention group
Group type: EXPERIMENTAL
Intervention: GFF MDI 18/9.6 μg
Number of subjects: 159
Study 27817811 — intervention group
Group type: EXPERIMENTAL
Intervention: GFF MDI 9/9.6 μg
Number of subjects: 159
Study 27817811 — intervention group
Group type: EXPERIMENTAL
Intervention: GFF MDI 4.6/9.6 μg
Number of subjects: 159
Study 27817811 — intervention group
Group type: EXPERIMENTAL
Intervention: GFF MDI 2.4/9.6 μg
Number of subjects: 159
Study 27817811 — intervention group
Group type: EXPERIMENTAL
Intervention: GFF MDI 1.2/9.6 μg
Number of subjects: 159
Study 27817811 — intervention group
Group type: COMPARATOR
Intervention: GP MDI 18 μg
Number of subjects: 159
Study 27817811 — intervention group
Group type: COMPARATOR
Intervention: FF MDI 9.6 μg
Number of subjects: 159
Study 27817811 — intervention group
Group type: COMPARATOR
Intervention: Open-label tiotropium 18 μg
Number of subjects: 159
Study 24918880 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal mattress
Number of subjects: 38
Study 24918880 — intervention group
Group type: COMPARATOR
Intervention: Thermal blanket
Number of subjects: 38
Study 22301084 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine induction for heroin users
Number of subjects: 228
Study 22301084 — intervention group
Group type: COMPARATOR
Intervention: Buprenorphine induction for prescription opioid users
Number of subjects: 228
Study 19330802 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (30 mg/day)
Number of subjects: 40
Study 19330802 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 17502270 — intervention group
Group type: EXPERIMENTAL
Intervention: BRP analysis
Number of subjects: 1552
Study 17502270 — intervention group
Group type: COMPARATOR
Intervention: Conventional methods
Number of subjects: 1552
Study 15140330 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 25mg
Number of subjects: 690
Study 15140330 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 50mg
Number of subjects: 690
Study 15140330 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 690
Study 15140330 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib (both dosages)
Number of subjects: 690
Study 11419425 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 4809
Study 11419425 — intervention group
Group type: COMPARATOR
Intervention: Abciximab
Number of subjects: 4809
Study 10436979 — intervention group
Group type: EXPERIMENTAL
Intervention: Zhuling polysaccharides combined with hepatitis B vaccine (group I)
Number of subjects: 286
Study 10436979 — intervention group
Group type: EXPERIMENTAL
Intervention: LAK cells induced by interleukin‐2 (IL‐2) transfusion therapy (group II)
Number of subjects: 286
Study 10436979 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacille Calmette‐Guerin (BCG) combined with persatin (group III)
Number of subjects: 286
Study 10436979 — intervention group
Group type: COMPARATOR
Intervention: Interferon (control group)
Number of subjects: 286
Study 10436979 — intervention group
Group type: COMPARATOR
Intervention: 10% glucose (control group)
Number of subjects: 286
Study 8177016 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Number of subjects: 9
Study 3065667 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 24
Study 3065667 — intervention group
Group type: COMPARATOR
Intervention: Prednisone
Number of subjects: 24
Study 31734931 — intervention group
Group type: EXPERIMENTAL
Intervention: Drama mode of school dental health education (SDHE)
Number of subjects: 360
Study 31734931 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified snake and ladder game mode of SDHE
Number of subjects: 360
Study 31734931 — intervention group
Group type: EXPERIMENTAL
Intervention: Flashcard mode of SDHE
Number of subjects: 360
Study 31734931 — intervention group
Group type: EXPERIMENTAL
Intervention: All modes of SDHE
Number of subjects: 360
Study 29279299 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glycemic therapy (target HbA1c <6.0%)
Number of subjects: 10251
Study 27494777 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol 400 mg every 4 weeks for ≤7.5 years
Number of subjects: 390
Study 27494777 — intervention group
Group type: COMPARATOR
Intervention: Control group (without early remission)
Number of subjects: 390
Study 24728846 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT) - 6000 impulses (energy flux density, 0.11 mJ/mm²) in three sessions after local anesthesia.
Number of subjects: 0
Study 24728846 — intervention group
Group type: COMPARATOR
Intervention: Placebo group - 6000 impulses of sham ESWT after local anesthesia.
Number of subjects: 0
Study 23491820 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple tailoring and counseling
Number of subjects: 414
Study 23491820 — intervention group
Group type: COMPARATOR
Intervention: Multiple tailoring only
Number of subjects: 414
Study 23491820 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 414
Study 19962288 — intervention group
Group type: EXPERIMENTAL
Intervention: Silexan (lavender oil preparation), 6-week intake
Number of subjects: 0
Study 19962288 — intervention group
Group type: COMPARATOR
Intervention: Lorazepam (benzodiazepine), 6-week intake
Number of subjects: 0
Study 19962288 — intervention group
Group type: EXPERIMENTAL
Intervention: Silexan and Lorazepam
Number of subjects: 0
Study 18541280 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafenoquine 200 mg bid for 3 days
Number of subjects: 1512
Study 18541280 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafenoquine 400 mg od for 3 days
Number of subjects: 1512
Study 18541280 — intervention group
Group type: COMPARATOR
Intervention: Primaquine plus doxycycline (22.5 mg + 100 mg daily for 14 days)
Number of subjects: 1512
Study 18541280 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafenoquine 200 mg od for 3 days
Number of subjects: 1512
Study 15645413 — intervention group
Group type: EXPERIMENTAL
Intervention: Recording from flexor carpi ulnaris
Number of subjects: 17
Study 15645413 — intervention group
Group type: COMPARATOR
Intervention: Recording from abductor digiti minimi
Number of subjects: 17
Study 12820077 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing literature reading course
Number of subjects: 170
Study 12820077 — intervention group
Group type: COMPARATOR
Intervention: Control group (no course)
Number of subjects: 170
Study 10998316 — intervention group
Group type: EXPERIMENTAL
Intervention: RSV inoculation (approximately 10^3 plaque‐forming units)
Number of subjects: 10
Study 8869096 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive care plus MLT (20 mg/day orally in the evening)
Number of subjects: 100
Study 8869096 — intervention group
Group type: COMPARATOR
Intervention: Supportive care alone
Number of subjects: 100
Study 8465554 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii (S.b.) 250 mg t.i.d. for 7 weeks
Number of subjects: 20
Study 8465554 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2871081 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultraviolet (UV) irradiation during surgery
Number of subjects: 30
Study 2871081 — intervention group
Group type: COMPARATOR
Intervention: Conventional ventilation without UV irradiation
Number of subjects: 30
Study 30526587 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction-stylet
Number of subjects: 97
Study 30526587 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction-no stylet
Number of subjects: 97
Study 30526587 — intervention group
Group type: EXPERIMENTAL
Intervention: Stylet-no suction
Number of subjects: 97
Study 30526587 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction
Number of subjects: 97
Study 30526587 — intervention group
Group type: EXPERIMENTAL
Intervention: No stylet
Number of subjects: 97
Study 30526587 — intervention group
Group type: COMPARATOR
Intervention: All procedures
Number of subjects: 97
Study 27376907 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine gel (10 ml)
Number of subjects: 100
Study 27376907 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (10 ml)
Number of subjects: 100
Study 25940250 — intervention group
Group type: EXPERIMENTAL
Intervention: Predischarge bundle intervention including smoking cessation counseling, screening for gastroesophageal reflux disease and depression or anxiety, standardized inhaler education, and a 48-h postdischarge telephone call.
Number of subjects: 172
Study 25940250 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care).
Number of subjects: 172
Study 25940250 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (bundle and control).
Number of subjects: 172
Study 24265523 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 850
Study 24265523 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 850
Study 21615492 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin supplementation
Number of subjects: 2